Skip to content
TrialScanner

NCT07617363

ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS

Phase 1RecruitingAPRECollaborator

Registry record

Lead sponsor
Washington University School of Medicine
Conditions
Acute Myeloid Leukemia; High-risk Myelodysplastic Syndrome
Primary completion
Oct 31, 2029Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT07617363 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

1 change recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT07617363: ATRN-119 in Combination With... | TrialScanner